```html

Jawbone Osteonecrosis: A Complete Patient Guide

Overview

Jawbone osteonecrosis (ONJ) is a condition in which a segment of the jawbone (maxilla or mandible) dies because its blood supply is compromised. When the bone tissue becomes necrotic, it may become exposed in the mouth, leading to pain, infection, and potential fracture.

Although the condition is considered rare, its prevalence is rising due to increased use of certain medications (especially anti‑resorptive drugs) and radiation therapy. Reported rates vary:

• Medication‑related ONJ (MRONJ) occurs in 0.1%–0.4% of patients taking oral bisphosphonates and up to 1%–2% of those receiving high‑dose intravenous formulations.<sup>1</sup>
• Radiation‑induced ONJ (osteoradionecrosis) is seen in 5%–15% of patients after head‑and‑neck cancer radiotherapy.<sup>2</sup>

Anyone can develop ONJ, but the condition most commonly affects:

• Older adults (≥55 years) taking bisphosphonates or denosumab for osteoporosis or metastatic cancer.
• Patients who have received radiation therapy to the jaws for head‑and‑neck malignancies.
• Individuals with underlying systemic illnesses that impair bone healing (e.g., diabetes, autoimmune disease).

Symptoms

Symptoms may develop gradually or suddenly, and many patients are initially asymptomatic. The most frequently reported signs include:

• Exposed bone: A visible, often painless, area of dead bone in the gum or palate that does not heal within 8 weeks.
• Pain or tenderness: Ranges from mild ache to severe throbbing, especially when chewing.
• Swelling or inflammation: Soft‑tissue edema around the affected site.
• Foul odor (halitosis) or discharge: From infected necrotic bone.
• Loose or mobile teeth: Due to loss of supporting bone.
• Difficulty opening the mouth (trismus): Resulting from muscle spasm or inflammation.
• Numbness or altered sensation: When the inferior alveolar nerve is involved.
• Pathological fracture: Rare but serious; the jaw may break under normal chewing forces.
• Weight loss or difficulty eating: Secondary to pain and reduced mouth opening.

Causes and Risk Factors

Medication‑related ONJ (MRONJ)

The majority of cases are linked to anti‑resorptive or anti‑angiogenic drugs that alter bone remodeling:

• Bisphosphonates: Oral (alendronate, risedronate) and intravenous (zoledronic acid, pamidronate).
• Denosumab: A monoclonal antibody that inhibits RANK‑L.
• Anti‑angiogenic agents: Bevacizumab, sunitinib, and others used in oncology.

Radiation‑induced ONJ (osteoradionecrosis)

High‑dose radiation damages the microvasculature of the jawbone, impairing healing. The risk rises with total doses > 50 Gy and when the mandible receives a high radiation field.

Other Contributing Factors

• Dental extractions or oral surgery: The most common precipitating event.
• Ill‑fitting dentures: Chronic trauma to the mucosa.
• Systemic diseases: Diabetes, anemia, immunosuppression, and steroid use.
• Smoking and alcohol: Both impair vascular supply.
• Poor oral hygiene: Increases bacterial load and infection risk.

Diagnosis

Early diagnosis is crucial to prevent progression. The diagnostic pathway typically includes:

Clinical Examination

• Inspection for exposed bone persisting > 8 weeks.
• Palpation for tenderness, swelling, and assessment of mouth opening.
• Dental charting to evaluate recent extractions, implants, or prosthesis use.

Imaging Studies

• Panoramic radiograph (OPG): First‑line; shows radiolucent areas, sequestra, or cortical erosion.
• Cone‑beam CT (CBCT): Provides three‑dimensional detail of bone defects, helpful for surgical planning.
• MRI: Useful to assess soft‑tissue involvement and differentiate infection from tumor recurrence.

Laboratory Tests

• Complete blood count and inflammatory markers (CRP, ESR) if infection is suspected.
• Serum calcium, vitamin D, and renal function for patients on bisphosphonates.

Biopsy

Rarely required, but a tissue sample may be taken to exclude malignancy when the presentation is atypical.

Treatment Options

Management depends on disease stage (AAOMS staging system) and patient factors. Options range from conservative measures to surgical reconstruction.

Conservative (Non‑Surgical) Care – Stage 0‑II

• Antibiotic therapy: Systemic coverage with amoxicillin‑clavulanate, clindamycin (if allergic), or metronidazole for anaerobes. Duration 2‑4 weeks, adjusted per culture.
• Antiseptic mouth rinses: 0.12% chlorhexidine twice daily.
• Pain control: Acetaminophen or NSAIDs (unless contraindicated); consider low‑dose opioids for severe pain.
• Modification of offending medication: Temporary discontinuation (“drug holiday”) of bisphosphonates or denosumab after discussion with the prescribing physician (often 2–3 months for oral bisphosphonates, 2 months for denosumab).
• Laser therapy: Low‑level laser can promote soft‑tissue healing and reduce pain (evidence Level B).

Surgical Intervention – Stage II‑III

• Debridement & sequestrectomy: Removal of necrotic bone while preserving healthy tissue.
• Resection & reconstruction: For extensive disease, segmental resection with a vascularized free flap (fibula or iliac crest) may be required.
• Primary closure: Tension‑free mucosal closure reduces exposure risk.
• Adjunctive therapies: Platelet‑rich plasma (PRP) or recombinant human bone morphogenetic protein‑2 (rhBMP‑2) can accelerate bone regeneration in selected cases.

Medications & Adjuncts

• Teriparatide (PTH 1‑34): Off‑label use in osteoporotic patients has shown bone healing benefits in small trials.
• Hyperbaric oxygen (HBO) therapy: 30–40 sessions at 2.0–2.5 ATA may improve vascularity, though data are mixed.

Lifestyle & Supportive Measures

• Maintain meticulous oral hygiene (soft brush, fluoride toothpaste).
• Avoid tobacco and limit alcohol.
• Use a well‑fitted denture; periodic adjustments by a prosthodontist.
• Nutrition: Soft, high‑protein diet to support healing.

Living with Jawbone Osteonecrosis

Daily Oral Care

• Brush gently twice daily with a soft‑bristled toothbrush.
• Rinse with chlorhexidine (0.12%) or a non‑alcoholic saline solution after meals.
• Floss cautiously; consider floss holders to avoid trauma.

Dietary Tips

• Prefer pureed, mashed, or soft foods while lesions heal.
• Include calcium‑rich (dairy or fortified alternatives) and vitamin D sources.
• Stay hydrated—dry mouth can increase infection risk.

Dental Follow‑up

• Schedule dental visits every 3–6 months for professional cleaning and monitoring.
• Ask the dentist to coordinate with your physician before any elective dental work.

Psychosocial Support

Chronic oral pain and aesthetic changes can affect mental health. Consider counseling, support groups, or online communities focused on ONJ.

Prevention

• Pre‑treatment dental assessment: Before starting bisphosphonates, denosumab, or head‑and‑neck radiation, have a comprehensive dental exam. Extract hopeless teeth and treat periodontal disease.
• Medication stewardship: Use the lowest effective dose and duration; reassess the need for anti‑resorptives annually.
• Good oral hygiene: Brush, floss, and use antimicrobial rinses.
• Avoid invasive dental procedures: When possible, use minimally invasive techniques; if extraction is unavoidable, employ prophylactic antibiotics and atraumatic technique.
• Smoking cessation: Improves vascular supply to the jaw.
• Manage systemic health: Keep diabetes, hypertension, and nutritional deficiencies under control.

Complications

If left untreated or inadequately managed, ONJ can lead to:

• Secondary infection: Osteomyelitis, cellulitis, or septicemia.
• Pathologic fracture: Mandibular fracture requiring fixation.
• Chronic pain and trismus: Limits nutrition and speech.
• Fistula formation: Abnormal communication between oral cavity and skin or sinus.
• Malignant transformation (rare): Chronic inflammation may predispose to squamous cell carcinoma.
• Psychological impact: Depression, anxiety, and reduced quality of life.

When to Seek Emergency Care

References

1. Mayo Clinic. “Osteonecrosis of the Jaw.” Accessed May 2024.
2. Centers for Disease Control and Prevention. “Head and Neck Cancers.” 2023.
3. American Association of Oral and Maxillofacial Surgeons (AAOMS). “Medication‑Related Osteonecrosis of the Jaw (MRONJ) Position Paper.” 2022.
4. National Institutes of Health. “Denosumab for Cancer‑Related Bone Disease.” 2023.
5. World Health Organization. “Oral Health Fact Sheet.” 2022.
6. Cleveland Clinic. “Osteoradionecrosis of the Jaw.” 2024.
7. Schweiger, A. et al. “Low‑Level Laser Therapy for MRONJ: A Systematic Review.” *J Oral Maxillofac Surg*, 2021.

```